Back to top

Image: Bigstock

Alnylam Pharmaceuticals, Inc.

Read MoreHide Full Article

Though Alnylam’s first-quarter posted a narrower loss and higher revenues compared to the year-ago period, the company is still a few years away from bringing a product to market. Any hiccup in the development process of the candidates may weigh heavily on the stock. However, Alnylam’s collaborations with several leading health care companies not only validate its RNAi platform technology, but also provide it with funds in the form of upfront, milestone and other payments. We are pleased with the company’s progress on its pipeline, especially the ATTR program. With multiple data read-outs lined up, 2015 is expected to be data-rich for the company.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>

Published in